A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Pfizer
Study ID
NCT07575906
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • PF-08057418 — DRUG
    solution or tablet (fasted/fed)
  • Placebo (A placebo does not have any medicine in it but looks just like the medicine being studied.) — OTHER
    solution or tablet (fasted/fed)

Study Details

The purpose of this clinical trial is to learn about the safety and pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from body after participant take it) of the study medicine (called PF-08057418) in healthy people. This study is seeking participants who are healthy adults. Everyone who participates in this study will receive the study medicine. The study medicine may be given as a solution or as a tablet. Participants will be dosed once a week for 5 weeks. The investigator will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe. Participants will be involved in this study for up to 13 weeks from screening to follow-up visit. Participants stay in the study clinic for the 5 week dosing duration of the study, with two follow-up visits subsequently, either in person or by telephone call.

Key Dates

Start date
May 8, 2026
Status verified
May 2026
Primary completion
Jul 23, 2026
Completion
Jul 23, 2026

Study Design

Enrollment
8 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: PF-08057418
    Participants will receive single oral solution or tablet dose(s) of PF-08057418
  • Placebo Comparator: Placebo
    Participants will receive single oral solution or tablet dose(s) of placebo.

Primary Outcome Measure

Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to 10 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Pfizer Clinical Research Unit -New HavenNew HavenConnecticut06511-

Find similar trials in New Haven, CT

By research site
Pfizer Clinical Research Unit -New Haven· New Haven, CT

Related Studies